

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 510-125

C# M#

KLIEWER et al

Group Art Unit: 1646

Serial No. 09/276,935

Examiner: Pak, M.

Filed: March 26, 1999

Date: January 29, 2002

Title: AN ORPHAN NUCLEAR RECEPTOR

Assistant Commissioner for Patents
Washington, DC 20231



RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

Sir:

AMENDMENT UNDER 37 CFR § 1.111

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	17	minus highest number		
previously paid for	34	(at least 20) =	0 x \$ 18.00	\$ 0.00

Independent claims after amendment	2	minus highest number		
previously paid for	6	(at least 3) =	0 x \$ 84.00	\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$ 0.00
--	---------

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$ 110.00
--	-----------

Terminal disclaimer enclosed, add \$ 110.00	\$ 0.00
---	---------

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)	\$ 0.00
<input type="checkbox"/> Please enter the previously unentered, filed	
<input type="checkbox"/> Submission attached	

Subtotal \$ 110.00

If "small entity," then enter half (1/2) of subtotal and subtract	-\$ 0.00
<input type="checkbox"/> Applicant claims "small entity" status. <input type="checkbox"/> Statement filed herewith	

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$ 0.00
--	---------

Assignment Recording Fee (\$40.00)	\$ 0.00
------------------------------------	---------

Other: INFORMATION DISCLOSURE STATEMENT FILED AUGUST 29, 2001	0.00
--	-------------

TOTAL FEE ENCLOSED \$ 110.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
GRT:ap

NIXON & VANDERHYE P.C.
By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: _____

Handwritten signature of Gary R. Tanigawa

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

KLIEWER et al.

Appln. No. 09/276,935

Filed: March 26, 1999

FOR: AN ORPHAN NUCLEAR RECEPTOR



Atty. Ref.: 510-125

Group Art Unit: 1646

Examiner: M. Pak

* * *

AMENDMENT UNDER 37 CFR § 1.111

January 29, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the pending Office Action (Paper No. 16) mailed October 2, 2001, entry and consideration of the following amendments and remarks are respectfully requested.

IN THE SPECIFICATION

Kindly enter the following amended paragraphs.

Pages 8-9, delete the second paragraph starting on page 8, line 10, and replace it with the following:

One embodiment of the receptor of the invention has the amino acid sequence set forth in Figure 1, or an analog thereof (wherein the term analog is intended to indicate a naturally occurring human variant of the Figure 1 sequence), or a fragment thereof, including fragments having at least one functional characteristic of hPXR (e.g., ligand binding or DNA binding). Preferred fragments include portions of the Figure 1 sequence at least 30 consecutive amino acids in length, more preferably, at least 50 consecutive amino acids in length, and most preferably, at least 75 consecutive amino acids in length. Specific fragments include the ligand binding domain (that is, amino acids 141 to 434 of the Figure 1 sequence) and the DNA binding domain (that is, amino acids 41 to 107 of the Figure 1 sequence) as well as the domain that is used for the